Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.

Composite image of rural village in Cambodia © MORU 2020.
An improvised village for forest workers, who sustain themselves with food gathered from the surrounding jungle.

Sponsored by University of Oxford and funded by the Global Fund Regional Component of the Regional Artemisinin-resistance Initiative (RAI2E) Grant, PAL is led by Principal Investigator Prof Richard Maude, with co-investigators MORU’s S. Sovannaroth, Tom Peto, James Callery, Mallika Imwong, Rupam Tripura, Mehul Dhorda, and Lorenz von Seidlein.

An estimated 2,000 participants who travel to the forest and stay overnight will receive either artemether-lumefantrine or multivitamin twice daily for 3 days followed by two doses weekly. They will be followed up every 28 days as they continue to visit the forest. Participants’ travel in the forest will be mapped to identify potential transmission sites and in-depth interviews conducted among forest goers, community leaders, healthcare workers and policymakers in Cambodia, Lao PDR and Thailand to assess the potential feasibility of prophylaxis in each country.

On 10 Feb, MORU and CNM organized an orientation meeting with the Provincial Health Department, Governor Office, local authorities, NGO partners, Village leaders and Village Malaria Workers to inform activities and aim of the PAL-Cambodia project. Following the site Initiation visit and training conducted by MORU’s Epidemiology and CTSG departments, the Cambodia team, led by Dr Rupam Tripura, has conducted engagement activities through schools and meetings with villagers.

Recruitment began on 10 March, and trial participants were given either artemether-lumefantrine or multivitamin and a mobile phone with a GPS logger installed for each group. Participants took pictures and shared some of the images while they stayed in the forest.

- Thank you, Rupam Tripura and James Callery for text and photos.

Similar stories

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

ASM Editor in conversation with Nick White

Malaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world’s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.